Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Tamara Madjid

Nurse Practitioner, Obstetrics & Gynecology Tulsa, OK Nurse Practitioner

NPI 1497908032 CMS profile 10905546

6600 S Yale Ave, Suite 1400, Tulsa, OK 74136

Open in the dashboard

General payments

$4,634

240 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tamara Madjid of Tulsa, OK is reported in the CMS Open Payments database as having received $4,634 across 240 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner, Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $951 66
2024 General $875 22
2023 General $777 41
2022 General $732 40
2021 General $1,298 71

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tamara Madjid
  • Nurse Practitioner, Obstetrics & Gynecology median
  • Middle half of Nurse Practitioner, Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Tamara Madjid were reported at $951. Among 1,030 Nurse Practitioner, Obstetrics & Gynecology profiles paid that year, the median was $151 and the middle half received between $51 and $371.

Show as a table
Year Tamara Madjid Nurse Practitioner, Obstetrics & Gynecology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,298 $135 $40–$338 $132
2022 $732 $143 $45–$386 $149
2023 $777 $153 $54–$411 $160
2024 $875 $140 $45–$326 $164
2025 $951 $151 $51–$371 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Mayne Pharma Inc. $950 61 payments
  2. AbbVie, Inc. $792 43 payments
  3. Astellas Pharma US Inc $583 13 payments
  4. Daiichi Sankyo Inc. $219 10 payments
  5. TherapeuticsMD, Inc. $208 14 payments
  6. Organon LLC $190 9 payments
  7. Pfizer Inc. $166 10 payments
  8. Evofem Biosciences, Inc. $166 16 payments
  9. Exeltis, USA Inc. $159 9 payments
  10. Millicent US Inc $158 8 payments
  11. Other $1,042 47 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,409 236 payments
  2. Education $200 2 payments
  3. Travel and Lodging $25 2 payments
Products named General payments · program years 2021–2025
  1. LO LOESTRIN FE $504 32 payments
  2. Veozah $360 10 payments
  3. ORILISSA $296 18 payments
  4. NEXTSTELLIS $249 10 payments
  5. ORIAHNN $227 15 payments
  6. INJECTAFER $219 10 payments
  7. ANNOVERA $208 14 payments
  8. IMVEXXY $208 14 payments
  9. Phexxi $166 16 payments
  10. PREMARIN $158 10 payments
  11. Other $2,515 112 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

240 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Obstetrics & Gynecology in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record